Search

Your search keyword '"Magenau, John M."' showing total 200 results

Search Constraints

Start Over You searched for: Author "Magenau, John M." Remove constraint Author: "Magenau, John M."
200 results on '"Magenau, John M."'

Search Results

4. A Phase 2 Trial of CD24Fc for Prevention of Graft-vs-Host Disease

5. Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012

6. Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes

8. Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients

9. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series

12. Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

13. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial

14. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission

15. Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

19. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma

22. Mitigating Damage Response with CD24 Fusion Protein for Prevention of Acute Graft-Versus-Host Disease

24. Targeting Danger Associated Molecular Pattern (DAMP) with CD24Fc to Reduce Acute Gvhd: Study Design on a Randomized Double Blind Placebo Controlled Phase III Clinical Trial (CATHY Study)

26. Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel

27. Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)

28. Rational Modification of Intestinal Microbiome and Metabolites after Allogeneic Hematopoietic Stem Cell Transplantation with Resistant Starch: A Pilot Study

29. Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial

30. Police unions and the police role

32. Ultrasensitive Genomic Minimal Residual Disease Detection in Peripheral Blood after Allogeneic HSCT for MDS Is Associated with Increased Relapse Risk and Inferior Survival

33. Impact of Individual Vs. Composite Endpoints for Prediction of Long-Term Survival in Gvhd Clinical Trials Research

34. Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study

35. The Effect of Azithromycin on Relapse in Patients with Moderate-Severe Chronic Graft Versus Host Disease (CGVHD)

36. Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel

37. Rational Modification of Human Gut Microbiome and Metabolites By Dietary Resistant Starch in Allogeneic Hematopoietic Stem Cell Transplantation: A Feasibility Study

38. Ultrasensitive Detection of Genomic Minimal Residual Disease before or after Allogeneic Hematopoietic Cell Transplantation for Adult AML is Associated with Inferior Survival

39. Correlation of Radiographic Abnormalities on Computer Tomography (CT) with Broncho-Alveolar Lavage (BAL) Results. What are Our Radiologists Reading?

40. Impact of Broncho-Alveolar Lavage on the Diagnosis and Management of Pulmonary Complications Following Hematopoietic Cell Transplantation

41. Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis

42. User-Centered Design and Development of a Personalized Mobile Health Application for Adult HCT Patients in the Inpatient Setting

45. Alpha 1 Anti-Trypsin (AAT): Novel Strategy to Treat Steroid Refractory Acute Graft Versus Host Disease

46. Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

48. 92 - Impact of Broncho-Alveolar Lavage on the Diagnosis and Management of Pulmonary Complications Following Hematopoietic Cell Transplantation

Catalog

Books, media, physical & digital resources